Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 206.74B |
| Revenue (ttm) | 54.75B |
| Net Income (ttm) | 16.22B |
| Shares Out | n/a |
| EPS (ttm) | 6.44 |
| PE Ratio | 12.74 |
| Forward PE | 10.69 |
| Dividend | 2.91 (3.50%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 1,924 |
| Average Volume | 4,106 |
| Open | 83.30 |
| Previous Close | 83.00 |
| Day's Range | 83.30 - 83.80 |
| 52-Week Range | 65.50 - 99.40 |
| Beta | 0.32 |
| RSI | 75.86 |
| Earnings Date | Oct 30, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart Condition
Merck & Co. Inc. (NYSE: MRK) on Tuesday released topline results from the Phase 2 CADENCE study of Winrevair (sotatercept-csrk) in adults for combined post- and precapillary pulmonary hypertension (C...
Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart Condition
Merck & Co. Inc. (NYSE: MRK) on Tuesday released topline results from the Phase 2 CADENCE study of Winrevair (sotatercept-csrk) in adults for combined post- and precapillary pulmonary hypertension (Cp...
Daily Dividend Report: MRK,PWR,MOS,GIS,PEG
Merck, known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the firs...
Merck (MRK) Increases Quarterly Dividend by 4.9%
Merck (MRK) Increases Quarterly Dividend by 4.9%
Merck (MRK) Increases Quarterly Dividend for 2026
Merck (MRK) Increases Quarterly Dividend for 2026
Merck raises quarterly dividend by 4.9% to $0.85/share
Merck raises quarterly dividend by 4.9% to $0.85/share, with a 3.54% yield. See payout dates and analysis.
Merck Announces First-Quarter 2026 Dividend
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2026 Dividend.
Merck Jumps On A Surprise Win; Why It Still Has A Long Road To Go
Merck stock jumped Tuesday on a surprise win for its drug, sotatercept, in patients with pulmonary hypertension.
Merck (MRK) Announces Significant Layoffs in New Jersey
Merck (MRK) Announces Significant Layoffs in New Jersey
Merck, Bristol announce additional layoffs in New Jersey
Merck Stock Rises as Heart-Drug Test Offers Hope for Post-Keytruda Era
Dow Movers: HD, MRK
In early trading on Tuesday, shares of Merck topped the list of the day's best performing Dow Jones Industrial Average components, trading up 1.7%. Year to date, Merck has lost about 5.1% of its value...
See Which Of The Latest 13F Filers Holds MRK
At Holdings Channel, we have reviewed the latest batch of the 146 most recent 13F filings for the 09/30/2025 reporting period, and noticed that Merck & Co Inc (Symbol: MRK) was held by 39 of these fun...
Merck's (MRK) Winrevair Achieves Key Goal in Pulmonary Hypertension Study
Merck's (MRK) Winrevair Achieves Key Goal in Pulmonary Hypertension Study
Merck’s Winrevair hits mid-stage trial success in new lung indication
Merck (MRK) Reports Promising Results from Phase 2 CADENCE Study
Merck (MRK) Reports Promising Results from Phase 2 CADENCE Study
Merck’s WINREVAIR (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 2 CADENCE study evaluating WINREVAIR (sotatercept-csrk) in adults for t...
Merck's WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)
WINREVAIR demonstrated a statistically significant and clinically meaningful reduction in the primary endpoint of pulmonary vascular resistance (PVR) compared to placebo, improving the ability of bloo...
Merck's WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck's WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With CpcPH due to HFpEF.
Merck Has Many Bullish Attributes (Technical Analysis)
Merck has bullish valuation metrics and is trading above its 30-week EMA with bullish long-term momentum. Learn why MRK stock is a Buy.
Merck (MRK) Sees Significant Revenue Potential from New Flu Drug
Merck (MRK) Sees Significant Revenue Potential from New Flu Drug
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover
One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.
Merck & Co., Inc. (MRK) M&A Call Transcript
Merck & Co., Inc. (MRK) Cidara Therapeutics, Inc., - M&A Call - Slideshow
Merck expects over $5 billion commercial opportunity from Cidara's flu drug
Merck said on Monday it expects a non-risk adjusted commercial opportunity in excess of $5 billion from Cidara Therapeutics' experimental flu drug.